THE DUDLEY GROUP NHS FOUNDATION TRUST FOI 011324 Question 2 Response shown in table below Question 4 - Please provide details of the number of applications for treatments used outside of their licensed indication (off-label) using the Cancer Drugs Fund made by your Trust for each month from April 2012 to November 2012 inclusive broken down by treatment and by indication - please find highlighted below in yellow. Vemurafenib Melanoma APRIL 2012 Bevacizumab (+IrMdG) CRC APRIL 2012 Panitumumab CRC APRIL 2012 Panitumumab CRC APRIL 2012 Bevacizumab (+IrMdG) CRC APRIL 2012 FolFOX = Oxaliplatin+5FU Pancreatic APRIL 2012 Bevacizumab (+Paclitaxel) mbreast (---) APRIL 2012 Vemurafenib Melanoma APRIL 2012 FolFOX = Oxaliplatin+5FU Pancreatic APRIL 2012 Bevacizumab (+Carbo/Taxane) Ovarian APRIL 2012 Everolimus mrcc APRIL 2012 Eribulin mbreast APRIL 2012 Imatinib GIST APRIL 2012 FolFOX = Oxaliplatin+5FU Pancreatic APRIL 2012 Cabazitaxel mcrpc MAY 2012 Abiraterone mcrpc MAY 2012
Lenalidomide Myelodysp 5q ETR MAY 2012 Bortezomib Myeloma MAY 2012 Fulvestrant HD (Faslodex) Breast MAY 2012 Cetuximab Head+Neck FEB 2012 Bevacizumab (+OxMdG) CRC MAY 2012 Abiraterone mcrpc MAY 2012 Bevacizumab (+OxMdG) CRC MAY 2012 Everolimus m.liver NET MAY 2012 Bevacizumab (+OxMdG) CRC JUNE 2012 Panitumumab CRC JUNE 2012 Bevacizumab (+OxMdG) CRC JUNE 2012 Rituximab Maintenance MCLymphoma JUNE 2012 Vemurafenib Melanoma JUNE 2012 Fulvestrant HD (Faslodex) Breast JUNE 2012 Fulvestrant HD (Faslodex) Breast JUNE 2012 Fulvestrant HD (Faslodex) Breast JULY 2012 Lapatinib (with Capecitabine) mbreast JULY 2012 Fulvestrant HD (Faslodex) Breast JULY 2012 FolfirinOX (5FU+Fol+Irin+OX) Pancreatic JULY 2012 Everolimus Caecal NET JULY 2012 Bevacizumab (+OxMdG) CRC JULY 2012 Bevacizumab (+OxMdG) CRC JULY 2012 Brentuximab Vedotin Hodgkins MAY 2012 Bendamustine + Rituximab CLL JULY 2012 Eribulin mbreast AUG 2012
Bevacizumab (+OxMdG) CRC SEPT 2012 Bevacizumab (+OxMdG) CRC AUG 2012 Ipilimumab Melanoma AUG 2012 FolFOX = Oxaliplatin+5FU Pancreatic SEPT 2012 Vemurafenib Melanoma SEPT 2012 Bevacizumab (+OxMdG) CRC SEPT 2012 Paclitaxel Albumin (Abraxane) Breast SEPT 2012 Bevacizumab (+OxMdG) CRC SEPT 2012 Rituximab Maintenance MCLymphoma SEPT 2012 Ipilimumab Melanoma SEPT 2012 Bevacizumab (+IrMdG) CRC SEPT 2012 Lapatinib (with Capecitabine) mbreast SEPT 2012 Rituximab Maintenance MCLymphoma SEPT 2012 Imatinib GIST OCT 2012 Bevacizumab (+IrMdG) CRC OCT 2012 Panitumumab CRC OCT 2012 Pemetrexed Maintenance NSCLC OCT 2012 Fulvestrant HD (Faslodex) Breast OCT 2012 Bevacizumab (+OxMdG) CRC OCT 2012 Ipilimumab Melanoma OCT 2012 Eribulin mbreast NOV 2012 Bevacizumab (+OxMdG) CRC NOV 2012 FolFOX = Oxaliplatin+5FU Pancreatic NOV 2012 Bevacizumab (+IrMdG) CRC NOV 2012 Bevacizumab (+IrMdG) CRC NOV 2012 Cabazitaxel mcrpc NOV 2012 Fulvestrant HD (Faslodex) Breast NOV 2012
Vemurafenib Melanoma NOV 2012 Panitumumab mcrc NOV 2012 Panitumumab mcrc NOV 2012 FolfirinOX (5FU+Fol+Irin+OX) Pancreatic NOV 2012 Rituximab Maintenance MCLymphoma NOV 2012
Trust Headquarters Russells Hall Hospital Dudley West Midlands DY1 2HQ Date: 17/01/2013 FREEDOM OF INFORMATION ACT 2000 - Ref: FOI/011324 With reference to your FOI request that was received on 21/12/2012 in connection with 'Cancer Drug Fund'. Your request for information has now been considered and the information requested is enclosed. Further information about your rights is also available from the Information Commissioner at: Information Commissioner Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF Tel: 0303 123 1113 Fax: 01625 524510 www.ico.gov.uk Yours sincerely Information Governance Manager Room 34a, First Floor, Esk House, Russells Hall Hospital, Dudley, DY1 2HQ Email: FOI@dgh.nhs.uk
Please find the responses to your request, in turn, below. Please confirm or deny whether your trust has submitted applications for treatments using the Cancer Drugs Fund between April 2012 and November 2012 inclusive. Confirmed Please supply details of the number of applications that your trust has submitted for treatments using the Cancer Drugs Fund during each month between April 2012 and November 2012 inclusive, broken down by cancer treatment and indication. Please find the response to question 2 attached Please confirm or deny whether your trust has submitted applications for treatments to be used outside of their licensed indication (off-label) using the Cancer Drugs Fund between April 2012 and November 2012 inclusive. Confirmed Please provide details of the number of applications for treatments used outside of their licensed indication (off-label) using the Cancer Drugs Fund made by your trust for each month from April 2012 to November 2012 inclusive, broken down by treatment, and by indication. Please find the response to question 4 attached